Management of acute type B aortic dissection

G. Chad Hughes, MD,a Nicholas D. Andersen, MD,a and Richard L. McCann, MDb

Acute type B aortic dissection (identified within 2 weeks of symptom onset), as described using the Stanford classification, involves the aorta distal to the left subclavian artery and accounts for 25%-40% of all aortic dissections. The traditional treatment paradigm of medical management for uncomplicated acute type B dissection and open surgical intervention for early or late complications of type B dissection is currently undergoing a period of evolution as a result of the influence of minimally invasive thoracic endovascular aortic repair options. Thoracic endovascular repair has replaced open surgical repair as the preferred treatment for complicated acute type B dissection, and may also prove beneficial for prophylactic repair of uncomplicated acute type B dissection for high-risk patients. This review discusses the management of acute type B aortic dissection and long-term treatment considerations. (J Thorac Cardiovasc Surg 2013;145:S202–7)

Acute type B dissections may be classified as uncomplicated or complicated, with complicated disease generally referring to the presence of rupture or impending rupture, malperfusion, and/or refractory pain or hypertension.1 Complicated dissections, which represent 15% to 20% of cases, require surgical or interventional therapy, and Thoracic endovascular aortic repair (TEVAR) has generally replaced open surgery or fenestration as the treatment of choice for this clinical problem.

For patients with dynamic malperfusion caused by branch vessel occlusion of the true lumen by the pressurized false lumen (Figure 1a, b), endovascular treatment aims to restore antegrade flow within the true lumen and reduce false lumen flow by stent graft coverage of the primary tear. Additional distal bare-metal stenting of the visceral segment and/or iliacs may be required to reexpand the distal true lumen, and femoral–femoral bypass may be required for long-segment unilateral iliac occlusion (Figure 2). For patients with static malperfusion caused by propagation of the dissection into branch vessel ostia with distal vessel occlusion (Figure 1), coverage of the primary tear and restoration of true lumen flow alone generally does not relieve the malperfusion syndrome, and thus endovascular treatment also requires branch vessel stenting (Figure 3), and surgical bypass may ultimately be required if endovascular attempts are unsuccessful.2 Regardless of the management approach, this form of malperfusion is associated with significant mortality, especially if the static malperfusion process involves the visceral vessels.3 For patients with contained or frank rupture (Figure 4), endovascular repair is more complex and requires sealing off the primary tear as well as the site of the leak, and frequently necessitates paving the entire thoracic aorta when the site of the leak is unclear.

Intravascular ultrasound and transesophageal echocardiography are superior to angiography for identifying primary and distal reentry tears, documenting guidewire position in the true lumen, assessing seal zones, and detecting endoleaks,4 and are used for all TEVAR dissection cases at our institution (Figure 5). We also consider intravascular ultrasound and transesophageal echocardiography assessment of the ascending aorta to be mandatory at the conclusion of each TEVAR case to assess for retrograde ascending aortic dissection, a catastrophic complication of TEVAR that occurs more frequently when treating dissection (Figure 5).5,6 Thoracic endovascular aortic repair is generally avoided in patients with connective tissue disease because of a high rate of treatment failure; however, endovascular therapy may provide a successful bridge to open treatment in select patients with connective tissue disease with complicated acute type B dissection, provided careful follow-up at an experienced aortic center is ensured.7,8

Observational data comparing endovascular therapy with open repair of acute complicated type B dissection favor overwhelmingly the endovascular approach. For example, the International Registry of Acute Aortic Dissection (IRAD) reported an in-hospital death rate of 33% for patients with acute complicated type B dissection treated by open surgery, compared with 11% for patients treated by endovascular therapy.9 A meta-analysis of 29 studies reporting outcomes after endovascular repair of acute complicated type B dissection further reported an in-hospital mortality rate of 9%.10 The use of TEVAR for complicated dissection remains

---

From the Division of Cardiovascular and Thoracic Surgery and the Division of Vascular Surgery. Duke University Medical Center, Durham, NC.

Disclosures: Dr Hughes is a consultant for Medtronic, St. Jude Medical, W.L. Gore and Associates, and Vascutek; a member of the speaker’s bureau for Medtronic, W.L. Gore and Associates, and Vascutek; and received unrestricted research grants from W.L. Gore and Associates and Vascutek. Drs Andersen and McCann have nothing to disclose with regard to commercial support.


Received for publication April 30, 2012; revisions received Oct 10, 2012; accepted for publication Nov 28, 2012; available ahead of print Dec 26, 2012.

Address for reprints: G. Chad Hughes, MD, Duke Heart Center, Division of Thoracic and Cardiovascular Surgery, Duke University Medical Center, Box 3051, Durham, NC 27710 (E-mail: gchad.hughes@duke.edu).

Copyright © 2013 by The American Association for Thoracic Surgery

http://dx.doi.org/10.1016/j.jtcvs.2012.11.078
investigational in the United States, although clinical trials to gain U.S. Food and Drug Administration approval are complete or nearly complete. Nonetheless, consensus statements from the Society of Thoracic Surgeons and the American Heart Association have already supported the use of TEVAR for acute complicated type B dissection.\(^1,12\)

**UNCOMPPLICATED ACUTE TYPE B DISSECTION**

Medical management with anti-impulse therapy has remained the preferred treatment option for uncomplicated acute type B dissection, with in-hospital mortality rates typically <10% with this strategy.\(^{13-15}\) Although interventional therapies may struggle to improve on medical management in the acute setting, when one examines longer term follow-up data, the results of medical management are less satisfactory. Data from IRAD reveal 3-year survival of medically managed patients discharged alive after hospitalization for acute type B dissection to be only 78%.\(^16\) Admittedly, a significant proportion of the late mortality is the result of patient comorbid conditions, but numerous studies have demonstrated that 25% to 50% of medically treated patients develop late aortic-related complications, most commonly aneurysmal degeneration of the false lumen.\(^1\) The upper thoracic aorta appears to be the major site of aneurysmal degeneration, with patency of the false lumen being the major risk factor for a late increase in aortic size.\(^17\)

Given that numerous reports have found that a thrombosed false lumen predicts lower event rates after type B dissection,\(^18\) many have speculated that prophylactic TEVAR for uncomplicated type B dissection may promote

---

**FIGURE 1.** Malperfusion syndromes. A, Dynamic malperfusion results in branch vessel obstruction by the intimal flap. The degree of obstruction can vary with changes in the cardiac cycle as well as with variations in pressure in the false lumen. This type of malperfusion syndrome is generally relieved via restoration of antegrade true lumen flow. B, Computed tomographic angiogram demonstrating dynamic malperfusion of the celiac axis. C, Static malperfusion results from extension of the dissection process into the branch vessel with subsequent distal occlusion. This malperfusion syndrome is not relieved by restoration of antegrade true lumen flow and requires branch vessel stenting or surgical bypass. D, Computed tomographic angiogram demonstrating static malperfusion of the superior mesenteric artery (SMA). Note that the dissection extends out into the SMA and that both true and false lumens are occluded distally within the SMA.\(^2,3\) \(F = \) false lumen; \(T = \) true lumen. Reprinted with permission from Elsevier.
false lumen thrombosis and prevent late aneurysm formation. The Investigation of Stent Grafts in Aortic Dissection trial attempted to study this question. The trial randomized low-risk, subacute (2-52 weeks from symptom onset) type B dissection patients to TEVAR or optimal medical management and found no difference in the primary end point of all-cause mortality at 2 years.\textsuperscript{19} Patients randomized to TEVAR did have significantly greater aortic remodeling, defined as true lumen recovery with thoracic false lumen thrombosis, which occurred in 91.3\% of TEVAR patients versus only 19.4\% of medically managed patients ($P < .001$). However, this did not translate into improved aorta-related survival, mainly because of a high rate of aorta-related deaths in the TEVAR group resulting from periprocedural technical complications. These complications, which included access vessel rupture, retrograde type A dissection, and thoracic aortic rupture despite TEVAR, were likely related to the short length of aortic pavement ($<15$ cm in most patients) and the use of an earlier generation thoracic device suboptimal for this application. The complication rate observed was much higher than would be considered acceptable in more recent series using devices better suited to this application.\textsuperscript{20} Furthermore, the trial had other limitations and does not represent the final word on this subject. Most notably, only patients who survived 2 weeks after symptom onset without intervention were included in the trial, potentially excluding high-risk patients who would be expected to derive the greatest benefit from early intervention. Last, although the results of medical management were good
for these low-risk patients, two thirds of the deaths in the medical management group were secondary to aortic rupture.

A number of studies have suggested several subsets of high risk uncomplicated patients who may benefit from early TEVAR. Specific predictors of early or late adverse events identified in multiple studies include an initial aortic diameter $\geq 4.0$ cm with a patent false lumen,\textsuperscript{15,21,22} an initial false lumen diameter $\geq 22$ mm in the proximal descending aorta,\textsuperscript{23} recurrent/refractory pain or hypertension,\textsuperscript{24} or intramural hematoma with development of a penetrating atherosclerotic ulcer in the proximal descending aorta\textsuperscript{15,22} (Table 1). However, uncertainty remains regarding the optimal management strategy for high-risk uncomplicated acute type B dissection, and the final answer to this question awaits a well-designed, prospective, randomized controlled trial.

**LONG-TERM MANAGEMENT**

Long-term mortality after hospital discharge is greater for type B dissection than for type A dissection, and attentive medical management and aortic surveillance are required. Specific predictors of follow-up mortality include female gender, prior aortic aneurysm, atherosclerosis, pleural effusion, and in-hospital acute renal failure, hypotension, or shock.\textsuperscript{16} Medical management with $\beta$-blockade and blood pressure control remains the cornerstone of long-term therapy for type B dissection\textsuperscript{25}; however, a recent report from IRAD also found that the use of calcium channel blockers at discharge was associated with improved long-term survival selectively in medically treated type B dissection patients.\textsuperscript{26} The mechanism of this mortality benefit was unclear, and the authors speculated that the findings may be the result of differences in the typically more elderly type B patient population as well as potential selective effects of calcium channel blockers on descending aortic remodeling. Regardless, the authors consider the results preliminary and hypothesis generating, and stress the need for randomized controlled trials to define more completely optimal medical management in this population.\textsuperscript{26}

Despite optimal medical management, at least one third of patients will require surgery for aortic-related complications within 5 years of the initial dissection, and the risk is most substantial within the first few months. Serial imaging at 1, 3, 6, and 12 months after discharge, and annually thereafter, is therefore recommended to allow for timely recognition and surgical repair of late problems of type B dissection, most commonly aneurysmal degeneration of a patent false lumen.\textsuperscript{25}

**CONCLUSIONS**

Treatment options for type B aortic dissection are evolving in the endovascular era. Medical management remains the preferred strategy for uncomplicated acute type B dissection, and medical compliance is critical (Figure 6). There remains little or no debate in the literature regarding the preferred choice of TEVAR for acute complicated type B dissection, but the potential role for TEVAR for high-risk uncomplicated type B dissection requires additional study. Close lifelong aortic surveillance to identify and repair problems of chronic dissection is mandatory for all patients.

![Figure 5](image-url) A, Intravascular ultrasound (IVUS) demonstrating true and false lumens and confirming true lumen guidewire access. B, Transesophageal echocardiography assessment of the proximal aorta at case completion demonstrating new retrograde type A dissection.

**TABLE 1. High-risk features of uncomplicated type B dissection**

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial aortic diameter $\geq 4.0$ cm with patent false lumen</td>
<td>15, 21, 22</td>
</tr>
<tr>
<td>Initial false lumen diameter $\geq 22$ mm in proximal DTA</td>
<td>23</td>
</tr>
<tr>
<td>IMH with PAU in proximal DTA</td>
<td>15, 22</td>
</tr>
<tr>
<td>Recurrent/refractory pain or hypertension</td>
<td>24</td>
</tr>
</tbody>
</table>

*DTA*, Descending thoracic aorta; *IMH*, intramural hematoma; *PAU*, penetrating atherosclerotic ulcer.
References


FIGURE 6. A case of type B dissection with rapid aneurysmal dilation resulting from medical noncompliance. A-C, A 30-year-old male with a history of malignant hypertension presented with an uncomplicated acute type B dissection with no high-risk anatomic features and was treated by medical management. D-F, At the 1-month follow-up visit, aortic diameters were stable but the patient’s blood pressure was poorly controlled. G and H, The patient missed all subsequent follow-up appointments and re-presented 16 months later with hypertensive urgency resulting from medical noncompliance. The maximal aortic diameter was found to have enlarged by 2 cm over the 16-month interval and was treated successfully by open extent 1 thoracoabdominal aortic aneurysm (TAAA) repair.


